miR-631的表达与卵巢上皮性癌预后的关系

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1444 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the data of epithelial ovarian carcinoma (EOC) patients in the Tumor and Cancer Gene Map (TCGA) database by analyzing the relationship between the expression of microRNA-631 (miR-631) and the clinicopathological features and prognosis of EOC patients and to investigate the effect of miR-631 on EOC cell migration and tumor volume. Methods: Clinical pathological features and corresponding microRNA expression date were extracted from TCGA database of 570 patients with EOC. The optimal cutoff value of miR-631 expression was calculated by X-tile software, and based on this optimal cutoff value the patients were grouped. The Kaplan-Meier curve and the Cox proportional hazards model was performed to assess the prognostic value of miR-631 expression in EOC patients. The miR-631 low-expressing EOC cell lines A2780, COV504 and miR-631 high-expressing cell lines ES2 and SKOV3 were selected by up-regulating the expression of miR-631 in low-expressing cell lines and down-regulating the expression in high-expressing cell lines to observe the ability of cell to migrate. The nude mouse EOC model was established and divided as the control group and miR-631 mimic group. The tumor volume of the two groups was observed. Results: Kaplan-Meier analysis showed that the overall survival (OS) of EOC patients with miR-631 low-level expression group (miR-631 expression value<4.78) was higher than that of EOC patients with miR-631 high-level expression group (miR-631 expression value≥4.78) (HR=0.65, 95%CI=0.47-0.89, P=0.008). Univariate and multivariate COX regression analysis revealed that miR-631 expression may be an independent factor influencing the prognosis of patients with EOC (HR=0.72, 95%CI=0.54-0.97, P=0.029). Up-regulation of miR-631 expression inhibits migration of EOC cells, and down-regulation of miR-631 expression promotes migration of EOC cells. Upregulation of miR-631 expression in the EOC nude mouse model reduced EOC tumor formation volume. Conclusion: Low expression of miR-631 may indicate poor prognosis in patients with EOC. Up-regulation of miR-631 can inhibit EOC migration and significantly reduce tumor volume, which may have therapeutic implications for EOC.

Key words： epithelial ovarian cancer miR-631 prognosis migration

Received: 25 September 2018

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Danyang
	LIANG Zongwen
	XU Chaoyi
	Yan Linzhi
	CHEN Feng
	ZHU Jiawei
	DUAN Ping

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I10/712

[1] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[2] LANGHE R. microRNA and ovarian cancer[J]. Adv Exp Med Biol, 2015, 889: 119-151.
[3] NAM E J, YOON H, KIM S W, et al. MicroRNA expression profiles in serous ovarian carcinoma[J]. Clin Cancer Res, 2008, 14(9): 2690-2695.
[4] SOPIK V, LQBAL J, ROSEN B, et al. Why have ovarian cancer mortality rates declined? Part II. Case-fatality[J]. Gynecol Oncol, 2015, 138(3): 750-756.
[5] KATO M, SLACK F J. microRNAs: small molecules with big roles-C. elegans to human cancer[J]. Biol Cell, 2008, 100(2): 71-81.
[6] VALENCIA-SANCHEZ M A, LIU J, HANNON G J, et al. Control of translation and mRNA degradation by miRNAs and siRNAs[J]. Genes Dev, 2006, 20(5): 515-524.
[7] ZHANG L, VOLINIA S, BONOME T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer[J]. Proc Natl Acad Sci U S A, 2008, 105(19): 7004-7009.
[8] PARKIN D M, BRAY F, FERLAY J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
[9] KLOOSTERMAN W P, PLASTERK R H. The diverse functions of microRNAs in animal development and disease[J]. Dev Cell, 2006, 11(4): 441-450.
[10] NIE D, GONG H, MAO X, et al. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study[J] Gynecol Oncol, 2019, 152(2): 259-264.
[11] MATTIE M D, BENZ C C, BOWERS J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J]. Mol Cancer, 2006, 5: 24.
[12] KOTA J, CHIVUKULA R R, O'DONNELL K A, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J]. Cell, 2009, 137(6): 1005-1017.
[13] 刘金立, 刘淑阁, 熊倩, 等. 急性单核细胞白血病特异性miRNA分子标志物的鉴定[J]. 温州医科大学学报, 2016, 46(10): 703-708, 715.
[14] BRAICU C, GULEI D, COJOCNEANU R, et al. miR-181a/b therapy in lung cancer: reality or myth?[J]. Mol Oncol, 2019, 13(1): 9-25.
[15] PARIKH A, LEE C, JOSEPH P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition[J]. Nat Commun, 2014, 5: 2977.
[16] LI R, SHI X, LING F, et al. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL[J]. Tumour Biol, 2015, 36(9): 7277-7283.
[17] XIA B, YANG S, LIU T, et al. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6[J]. Mol Cancer, 2015, 14: 57.
[18] KINOSE Y, SAWADA K, NAKAMURA K, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma[J]. Oncotarget, 2015, 6(13): 11342-11356.
[19] MITRA A K, CHIANG C Y, TIWARI P, et al. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis[J]. Oncogene, 2015, 34(48): 5923-5932.
[20] WEN C, LIU X, MA H, et al. miR‑338‑3p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2 [J]. Int J Oncol, 2015, 46(5): 2277-2285.
[21] LIANG H, JIANG Z, XIE G, et al. Serum microRNA-145 as a novel biomarker in human ovarian cancer[J]. Tumour Biol, 2015, 36(7): 5305-5313.
[22] GAO Y C, WU J. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer[J]. Tumour Biol, 2015, 36(6): 4843-4850.
[23] KIM T H, SONG J Y, PARK H, et al. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma[J]. Cancer Lett, 2015, 356(2 Pt B): 937-945.
[24] YU X, DHAKAL I B, BEGGS M, et al. Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity[J]. Toxicol Sci, 2010, 118(2): 391-403.
[25] XI H, LI L, DU J, et al. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10[J]. Oncol Rep, 2017, 37(2): 961-968.